• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket

    3/17/23 7:21:30 AM ET
    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Other Consumer Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASPU alert in real time by email

    Gainers

    • Enzo Biochem, Inc. (NYSE:ENZ) shares rose 89.9% to $2.26 in pre-market trading after the company announced it will sell its clinical laboratory to Labcorp.
    • Histogen Inc. (NASDAQ:HSTO) climbed 32.3% to $1.15 in pre-market trading as the company announces issuance of US patent covering CTS-2090 methods of use.
    • HUB Cyber Security (Israel) Ltd. (NASDAQ:HUBC) gained 23.8% to $2.96 in pre-market trading after jumping over 20% on Thursday.
    • Procaps Group S.A. (NASDAQ:PROC) rose 16.6% to $4.79 in pre-market.
    • Biofrontera Inc. (NASDAQ:BFRI) gained 15.6% to $0.73 in pre-market trading.
    • PaxMedica, Inc. (NASDAQ:PXMD) gained 14.4% to $2.55 in pre-market trading.
    • FedEx Corporation (NYSE:FDX) shares rose 11.7% to $228.00 in pre-market trading after the company reported better-than-expected Q3 EPS and raised its FY23 outlook.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) shares rose 6.6% to $8.13 in pre-market trading after reporting Q4 results.
    • United States Steel Corporation (NYSE:X) shares rose 5.6% to $25.90 in pre-market trading after the company issued strong Q1 guidance.
    • Baidu, Inc. (NASDAQ:BIDU) rose 5.2% to $145.32 in pre-market trading. Baidu shares saw redemption after brokerages, including Citigroup, granted their preliminary approval to its ChatGPT counterpart.

    Losers

    • Diebold Nixdorf, Incorporated (NYSE:DBD) fell 23% to $1.77 in pre-market after declining 2% on Thursday.
    • Virgin Orbit Holdings, Inc. (NASDAQ:VORB) fell 22.1% to $0.5502 in pre-market trading. Virgin Orbit shares dipped 30% on Thursday after the company announced a company-wide operational pause in order to conserve capital while it conducts discussions with potential funding sources and explores strategic opportunities.
    • Bruush Oral Care Inc. (NASDAQ:BRSH) fell 19.9% to $0.2250 in pre-market trading after gaining 3% on Thursday.
    • Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares fell 19.2% to $120.90 in pre-market trading after the company said that that FDA has decided to hold a public advisory committee meeting on SRP 9001 BLA.
    • ThermoGenesis Holdings, Inc. (NASDAQ:THMO) fell 18.2% to $4.91 in pre-market trading after jumping 43% on Thursday. ThermoGenesis announced a $3 million private placement.
    • Optex Systems Holdings, Inc (NASDAQ:OPXS) shares dropped 17.8% to $2.59 in pre-market trading after declining over 9% on Thursday.
    • Aspen Group, Inc. (NASDAQ:ASPU) fell 12.1% to $0.1099 in pre-market trading after dropping 7% on Thursday.
    • Loyalty Ventures Inc. (NASDAQ:LYLT) fell 9.7% to $0.1311 in pre-market trading after dipping 46% on Thursday.
    • Unique Fabricating, Inc. (NASDAQ:UFAB) fell 9.1% to $0.2201 in pre-market trading after surging more than 20% on Thursday.
    • CXApp Inc. (NASDAQ:CXAI) shares fell 6% to $3.78 in pre-market trading.

    Now Read This: Top 5 Materials Stocks That Are Set To Fly

    Get the next $ASPU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPU
    $BFRI
    $BIDU
    $BRSH

    CompanyDatePrice TargetRatingAnalyst
    FedEx Corporation
    $FDX
    3/20/2026$360.00Reduce → Hold
    HSBC Securities
    FedEx Corporation
    $FDX
    3/20/2026$383.00 → $426.00Buy
    TD Cowen
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    FedEx Corporation
    $FDX
    2/25/2026$335.00Hold → Reduce
    HSBC Securities
    FedEx Corporation
    $FDX
    2/13/2026$313.00 → $383.00Buy
    TD Cowen
    MARA Holdings Inc.
    $MARA
    2/9/2026$8.00Underweight
    Morgan Stanley
    FedEx Corporation
    $FDX
    2/3/2026$380.00Equal Weight → Overweight
    Wells Fargo
    FedEx Corporation
    $FDX
    2/3/2026$427.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP of Operational Excellence Baur Frank Tobias bought $32,284 worth of shares (700 units at $46.12), increasing direct ownership by 2% to 38,572 units (SEC Form 4)

    4 - DIEBOLD NIXDORF, Inc (0000028823) (Issuer)

    5/9/25 4:26:50 PM ET
    $DBD
    Office Equipment/Supplies/Services
    Miscellaneous

    EVP CHIEF FINANCIAL OFF Dietrich John W bought $273,980 worth of shares (1,000 units at $273.98), increasing direct ownership by 12% to 9,067 units (SEC Form 4)

    4 - FEDEX CORP (0001048911) (Issuer)

    1/8/25 7:43:16 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    Director Lane Amy B bought $91,929 worth of shares (333 units at $276.06) (SEC Form 4)

    4 - FEDEX CORP (0001048911) (Issuer)

    12/26/24 5:08:58 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Martin R Brad

    4 - FEDEX CORP (0001048911) (Issuer)

    3/23/26 5:25:38 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 4 filed by Thiel Frederick G

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    3/19/26 7:00:03 PM ET
    $MARA
    EDP Services
    Technology

    SEC Form 4 filed by Khan Salman Hassan

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    3/19/26 7:00:02 PM ET
    $MARA
    EDP Services
    Technology

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FedEx upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded FedEx from Reduce to Hold and set a new price target of $360.00

    3/20/26 10:14:10 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    TD Cowen reiterated coverage on FedEx with a new price target

    TD Cowen reiterated coverage of FedEx with a rating of Buy and set a new price target of $426.00 from $383.00 previously

    3/20/26 8:04:01 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    MARA Holdings Inc. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded MARA Holdings Inc. from Buy to Neutral

    2/27/26 11:05:23 AM ET
    $MARA
    EDP Services
    Technology

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MARA Holdings, Inc. Announces $1.0 Billion Repurchase of 0.00% Convertible Senior Notes due 2030 and 2031 and Sale of 15,133 Bitcoin

    Miami, FL, March 26, 2026 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ:MARA) ("MARA" or the "Company"), a leading digital energy and infrastructure company, today announced that it has entered into privately negotiated repurchase agreements with certain holders of its outstanding 0.00% Convertible Senior Notes due 2030 (the "2030 Notes") and 0.00% Convertible Senior Notes due 2031 (the "2031 Notes" and, together with the 2030 Notes, the "Notes") to repurchase approximately $367.5 million in aggregate principal amount of the 2030 Notes for an aggregate cash repurchase price of approximately $322.9 million and approximately $633.4 million in aggregate principal amount of the 2031 Notes fo

    3/26/26 8:05:00 AM ET
    $MARA
    EDP Services
    Technology

    Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

    In early clinical results, Sarepta's αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and DM1 Company to host investor call on March 25, 2026, at 8:30 a.m. Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first clinical results from two of its siRNA programs for neuromuscular diseases. Early results from Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1) demonstrated dose- dependent muscle exposure, early biomarker effects, and favorabl

    3/25/26 8:05:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need

    3/24/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Sarepta Therapeutics Inc.

    SCHEDULE 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    3/27/26 1:00:25 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MARA Holdings Inc.

    SCHEDULE 13G/A - MARA Holdings, Inc. (0001507605) (Subject)

    3/27/26 10:32:18 AM ET
    $MARA
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by FedEx Corporation

    SCHEDULE 13G/A - FEDEX CORP (0001048911) (Subject)

    3/26/26 6:20:23 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Leadership Updates

    Live Leadership Updates

    View All

    Aspen Group Announces Leadership Transition

    PHOENIX, March 16, 2026 (GLOBE NEWSWIRE) -- Aspen Group, Inc. ("AGI") (OTCQB:ASPU), an education technology holding company and the parent company of Aspen University (AU) and United States University (USU), announced today a leadership transition designed to support the company's next phase of growth and operational execution. Effective today, March 16, Matt LaVay, currently Chief Financial Officer of Aspen Group, will assume the role of Chief Executive Officer and will join the Aspen Group Board of Directors. Michael Mathews, who has served as Chief Executive Officer since 2012, will transition to Executive Chairman of the Board. The leadership transition is part of the company's planne

    3/16/26 8:00:00 AM ET
    $ASPU
    Other Consumer Services
    Consumer Discretionary

    FedEx Appoints Scott Ray as Chief Operating Officer for U.S. and Canada Surface Operations

    FedEx Corp. (NYSE:FDX) today announced the appointment of Scott Ray as chief operating officer for U.S. and Canada Surface Operations, effective June 1. He will begin transitioning into the role as COO-elect on Feb. 1. Reporting to FedEx President and CEO Raj Subramaniam, Ray will be the newest member of the FedEx Executive Committee, succeeding John Smith, who will transition to CEO of FedEx Freight as of June 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126094399/en/FedEx appoints Scott Ray as chief operating officer of Surface Operations in U.S. and Canada Ray will be responsible for leading all aspects of Surface Ope

    1/27/26 8:31:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    FedEx Announces Board of Directors for Future Independent FedEx Freight

    Board includes veteran leaders with transportation and logistics, financial, and technology expertise FedEx Corp. (NYSE:FDX) today announced the ten-member board of directors for FedEx Freight, ahead of its planned spin-off from FedEx Corp. on June 1, 2026. As previously announced, R. Brad Martin, current executive chairman of the FedEx Corp. board of directors, will serve as chairman of the board of FedEx Freight. John Smith, the incoming president and chief executive officer of FedEx Freight, will also serve as a director, alongside eight other highly experienced leaders across the transportation and logistics, supply chain management, and technology sectors. "We've assembled a grou

    1/16/26 8:01:00 AM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Financials

    Live finance-specific insights

    View All

    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wed., March 25, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present the early clinical results from the Phase 1/2 ascending dose studies of SRP-1001 for facioscapulohumeral muscular dystrophy type 1 (FSHD1) and SRP-1003 for myotonic dystrophy type 1 (DM1). The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need

    3/24/26 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FedEx Reports Strong Third Quarter Results

    Raises Full-year Fiscal 2026 Earnings Outlook On Track to Spin Off FedEx Freight on June 1, 2026 FedEx Corp. (NYSE:FDX) today reported the following consolidated results for the third quarter ended February 28 (adjusted measures exclude the items listed below):   Fiscal 2026   Fiscal 2025   As Reported (GAAP)   Adjusted (non-GAAP)   As Reported (GAAP)   Adjusted (non-GAAP) Revenue $24.0 billion   $24.0 billion   $22.2 billion   $22.2 billion Operating income $1.35 billion   $1.62 billion   $1.29 billion  

    3/19/26 4:06:00 PM ET
    $FDX
    Air Freight/Delivery Services
    Consumer Discretionary

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPU
    $BFRI
    $BIDU
    $BRSH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13G/A filed by MARA Holdings Inc.

    SC 13G/A - MARA Holdings, Inc. (0001507605) (Subject)

    11/14/24 6:13:30 PM ET
    $MARA
    EDP Services
    Technology